Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 721 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations August 13, 2018 Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 Identical Twins Find Strength in Shared Breast Cancer Battle After Being... November 6, 2019 FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma October 27, 2025 Load more HOT NEWS Women at High Risk of Breast Cancer Find it Hard to... EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... FDA Approves Ivosidenib for Myelodysplastic Syndromes
